Richard A. Koup

Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans

This study shows that sequential vaccination can mature VRC01-class B cells into antibodies that neutralize a broad range of HIV-1 viruses.

Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells

The paper identifies distinct follicular helper CD4 T cell programming in HIV-positive individuals who produce broadly neutralizing antibodies, linking it to improved B cell follicle architecture and reduced suppressor cells.

HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV vectored immunotherapy in humanized mice

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.

Multivariate analysis of glycogenes reveals coordinated regulation of immunoglobulin glycosylation in an immortalized human B cell system

The paper uses cytokine perturbations in B cells to analyze glycogene expression and IgG glycosylation, identifying cytokine-specific signatures and glycosylation profiles.

Antibody-mediated cellular responses are dysregulated in Multisystem Inflammatory Syndrome in Children (MIS-C)

This study identifies dysregulated antibody-mediated cellular responses in MIS-C, linking NK cell dysfunction to immune pathology and suggesting potential therapeutic interventions.